n eoadjuvant chemoradiation (CRt) followed by proctectomy is the recommended treatment for patients with locally advanced rectal cancer and it improves outcomes. [1] [2] [3] [4] there is a variability in treatment responses ranging from complete histologic regression ( pathologic complete response) to progression of disease. Response to therapy reflects the underlying biology of the tumor and could serve as a surrogate for expected outcome. 5 tumor regression grading systems have been proposed and used in europe, but have not been routinely adopted in the united states. 6 experience with established regression grading systems has shown that patients with pathologic complete response experience better oncologic outcomes, and nonresponders experience inferior oncologic outcomes. [7] [8] [9] [10] although these studies demonstrate clinical applicability for the extremes of response to therapy, the majority of patients with rectal cancer have a partial response to neoadjuvant CRt, the implications of which are not clearly understood.
Response to CRt was initially incorporated into the posttreatment t stage, or ypt stage, of the american Joint Commission on Cancer (aJCC) tnm staging system for rectal cancer. however, the tnm staging system was not designed to capture detailed information about the degree of response to CRt and was understandably inadequate when adapted for this purpose. in 2010, the aJCC and the College of american Pathology (CaP) published guidelines for grading rectal cancer response to neoadjuvant CRt, with the intention of standardizing reporting and improving clinician access to information regarding treatment response. 4 the 4-category regression grading guidelines published by the aJCC/CaP were adapted from a 3-category grading scheme proposed by Ryan and colleagues. 11 although these guidelines were established based on expert consensus and previous studies demonstrating the prognostic value of various other regression grading systems, the clinical relevance of the aJCC/CaP regression grading system for rectal cancer was not established before its release. 4 the aJCC/CaP grading system includes 2 partial response grades, with the premise that incremental improvement in response serves as a surrogate for better outcomes, but this concept has not been validated. We hypothesize that aJCC/CaP regression grade is indeed associated with significant differences in oncologic outcome, and the ultimate goal of this study is to determine prognosis based on the aJCC/CaP tumor grading system.
METHODS

Study Population and Data Collection
all patients enrolled in this study were identified from a prospectively maintained, single-institution, institutional review board-approved colorectal cancer database. all patients were consented for enrollment into the database, and this study was incorporated within the institutional review board-approved parameters for appropriate use of the database. a query was made for patients meeting inclusion criteria of first diagnosis of rectal cancer treated with preoperative CRt between January 1992 and December 2012. exclusion criteria were failure to undergo proctectomy, failure to complete CRt, nonadenocarcinoma histology, presence of noncolorectal malignancy, and incomplete pathologic or survival data.
Treatment Characteristics
this study is retrospective and did not adhere to a predefined treatment protocol. all patients received neoadjuvant therapy and surgery at a single institution, and all patients included in the study were treated with curative intent. in general, patients with stage ii and iii disease were offered neoadjuvant CRt. some patients with earlier stage disease were offered neoadjuvant therapy based on tumor location, and patient and provider preference. Patients with stage iV disease were offered neoadjuvant CRt when proctectomy and metastasectomy were planned. neoadjuvant chemotherapy regimen was 5-fluorouracil based and was either delivered intravenously or orally. target neoadjuvant radiotherapy dosing was 5040 cGy. all patients with stage ii, iii, and iV disease were offered adjuvant chemotherapy, and, for those who underwent therapy, the regimen was selected on an individualized basis. Patients were offered additional chemotherapy, radiation, and/or resection for the treatment of recurrence.
Pathologic Response Grading
Pathologic responses to neoadjuvant CRt were scored by using the criteria developed by the aJCC and CaP. the grades are defined as follows: grade 0 (complete response), no viable cancer cells; grade 1 (moderate response), single or small groups of cancer cells; grade 2 (minimal response), residual cancer outgrown by fibrosis; and grade 3 (poor response), minimal or no tumor kill, extensive residual cancer. aJCC/CaP regression grading was adopted as a standard operating procedure by the Cleveland Clinic Pathology Department in 2011. for patients who underwent surgery between 2011 and 2012, aJCC/CaP regression grade was determined by the departmental Gi pathologist assigned to each surgical case (8 total pathologists grading cases). for patients treated during this period, the aJCC/CaP regression grade was determined by chart review. for patients who underwent surgery between 1992 and 2010, aJCC/CaP regression grade was determined ad hoc by 1 of 2 Gi pathologists blinded to patient outcome. eligible patients whose slides could not be obtained for review were excluded from the study. in cases where grading was unclear, the case was reviewed by 2 or more pathologists, and grading was determined by consensus. all pathologists involved received specific training in aJCC/CaP regression grading of rectal cancer. the final aJCC/CaP response grade was used to define the study cohorts. Patient and tumor data for each cohort are shown in table 1.
Outcome Measures
the primary outcome measures of this study were survival and cancer recurrence rates. three survival outcomes were assessed: overall survival, disease-free (recurrence-free) survival, and cancer-specific survival. three recurrence outcomes were also assessed: overall recurrence, local recurrence, and distant recurrence. five-year survival and recurrence probabilities, as well as Kaplan-meier survival curves, were compared with identify differences in outcome related to aJCC/CaP regression grade. as a secondary outcome, significant relationships between aJCC/CaP regression grade and oncologically important covariates, such as pathologic stage, were identified and included in multivariate survival models. 
Statistical Analysis
Patient and tumor characteristics were compared for patients with each aJCC/CaP grade. Categorical variables were expressed by frequency and percentage and were compared between aJCC/CaP grades by using a χ 2 test. normally distributed continuous variables were expressed as mean ± sD and were compared between aJCC/ CaP grades by using anoVa. Continuous variables that were not normally distributed or had unequal variance were expressed as median and range and compared by using nonparametric statistics (Kruskal-Wallis rank sum test). median follow-up times for survival outcomes were estimated and compared among cohorts by Kaplanmeier analysis of the censoring distribution. univariate survival and recurrence analysis was performed by using the Kaplan-meier method, and the equality of survival distributions for the different aJCC/CaP response grades was tested by using pooled log-rank (mantel-Cox) comparisons. Kaplan-meier analysis was also performed for significant covariates such as pathologic stage, and variables with p < 0.10 in these analyses were used in multivariate analyses. Patients with missing data were excluded from multivariate analyses in a listwise fashion, so only variables with n < 15% were selected for use in multivariate survival modeling. final multivariate models were constructed by using forward stepwise likelihood ratio Cox proportional hazards regression with forced entry of aJCC/CaP grade. Criteria for stepwise regression were p < 0.05 for entry and p > 0.10 for removal. for categorical variables, the variable with the highest event rate was selected as the reference category to maximize the sensitivity of multivariate analyses. statistical analysis was performed by using sPss v21 (iBm, armonk, nY) and R v3.0.2; figures were compiled by using adobe illustrator Cs6 (adobe systems incorporated, san Jose, Ca).
RESULTS
Patient Characteristics
our initial database query resulted in 615 consecutive patients meeting the inclusion criteria. seventy-seven patients were rejected because they met 1 or more exclusion criteria, resulting in a final study population of 538 nonconsecutive patients. one hundred five patients (19.5%) had an aJCC/CaP grade 0 response to CRt, 153 patients (28.4%) had a grade 1 response, 181 patients (33.6%) had a grade 2 response, and 99 patients (18.4%) had a grade 3 response to CRt. images representative of each aJCC/ CaP regression grade are displayed in figure 1 . the median length of follow-up in this study was 4.8 years. Patient demographics are shown in table 1, and tumor characteristics are shown in table 2. several important factors exhibited covariance with aJCC/CaP response grade. Patients with poor response grades tended to have higher frequency of angiolymphatic invasion and positive margins (nearly always at the radial margin). there was a significant association between aJCC/CaP response grade and pathologic staging parameters. setting aside the obvious association between aJCC/CaP grade and ypt stage, patients with poorer responses to neoadjuvant CRt were significantly more likely to have node-positive (p < 0.01) or metastatic disease (p < 0.01) than patients with more favorable responses to CRt, resulting in a close association between aJCC/CaP grade and overall pathologic stage.
Consistent with previous findings by our group, patients with a longer rest period between completion of CRt and surgery tended to have improved response grades. 12 other treatment characteristics, such as the neoadjuvant chemotherapy protocol, number of patients receiving adjuvant chemotherapy, or time of entry into the study did not differ significantly between the cohorts. the interaction among neoadjuvant chemotherapy regimen, time of treatment (within the study interval), and aJCC/ CaP regression grade achieved was not significant. , p = 0.01). Pairwise significance testing of Kaplan-meier curves for patients with each aJCC/CaP regression grade demonstrated that aJCC/ CaP regression grades of 0 and 3 were associated with patterns of survival and recurrence that were distinct from all other grades (table 3) . for the outcomes of overall and disease-free survival, the difference between every regression grade was statistically significant, including the difference between the 2 partial response categories (table 3) .
Kaplan-Meier Survival Analysis
Kaplan-meier survival functions were used to estimate 5-year survival and recurrence probabilities each cohort (table 4) . american Joint Committee on Cancer/ College of american Pathologists regression grade was associated with significant differences in 5-year overall survival (p < 0.001), disease-free survival (p < 0.001), cancer-specific survival (p < 0.001), overall recurrence (p < 0.001), and distant recurrence probabilities (p = 0.006). notably, the local recurrence rate in our population was very low (2.4%), which substantially decreased the sensi-tivity of significance testing. the fact that no local recurrences were observed in any of the 99 aJCC/CaP grade 0 patients may be indicative of an important relationship between aJCC/CaP regression grade and local recurrence rate. however, other predictors of recurrence, such as histologic positive margin, are significantly associated with aJCC/CaP regression grade and confound the ability to draw any definite conclusion.
Kaplan-meier analysis was performed on all patient, tumor, and treatment characteristic variables to identify significant covariates for each survival and recurrence outcome. Variables that were associated with significant differences in survival and/or recurrence were age, angiolymphatic invasion, asa classification, Bmi, length of postoperative hospital stay, pathologic stage, ypt stage, pathologic n stage, m stage, histologic positive margin, previous colorectal surgery, surgical procedure, rest period between completion neoadjuvant therapy and surgery, and tumor perforation. these factors were used to construct multivariate survival models. other factors, such as adjuvant chemotherapy treatment, were not found to significantly affect survival or recurrence in our population.
Cox Proportional Hazards Regression
for each survival and recurrence outcome, multivariate Cox proportional hazards regression models were constructed to adjust the effect of aJCC/CaP grade on oncologic outcome for significant covariates. significant covariates in survival analyses included age, pathologic stage, histologic margin status, surgical procedure, and tumor perforation (table 5) . aJCC/CaP response grade was a significant independent predictor of overall survival (p < 0.001), disease-free survival (p = 0.001), and cancerspecific survival (p = 0.006), where each aJCC/CaP regression grade was associated with a distinct mortality risk compared with nonresponders (aJCC/CaP grade 3). the only significant covariates in analyses of recurrence were surgical procedure and pathologic stage (table 6). aJCC/ CaP grade was an independent predictor of overall recurrence (p = 0.001), but not local or distant recurrence when analyzed individually. all Cox regression analyses were recomputed, by using the same covariates, to model the effect of a single aJCC/CaP grade increase on each outcome of interest (table 7) . aJCC/CaP grade increase was associated with a statistically significant increase in risk in analyses of overall survival (p < 0.001), disease-free survival (p < 0.001), cancer-specific survival (p = 0.001), and overall recurrence (p < 0.001).
DISCUSSION
this study presents the aJCC/CaP tumor regression grading system as an independent prognostic factor for patients who have rectal cancer treated with neoadjuvant CRt. We found that not only complete response (grade 0) and poor response (grade 3) grades, but also the partial response grades (grades 1 and 2) defined by the aJCC/CaP, were associated with distinct 5-year survival and recurrence probabilities in comparison with poor responders (grade 3). aJCC/CaP regression grade was also associated with other known prognostic factors including angiolymphatic invasion, nodal metastasis, and pathologic stage. even after adjusting for those established prognostic factors in multivariate analyses, aJCC/CaP regression grade correlated well with overall survival, disease-free survival, cancer-specific survival, and overall recurrence. many regression grading systems have been proposed for rectal cancer. 6 although these systems are useful and, in some cases, prognostic, none has been widely used in the united states. the aJCC/CaP recognized the potential value of tumor regression grading and developed a set of consensus guidelines for regression grading in 2010 that they support for national implementation. 4 the major strengths of this study are that it establishes the clinical relevance of the aJCC/CaP regression grading system in a large patient population and achieves adequate follow-up by retrospective grading of patients treated before the release of the guidelines. the novel finding that aJCC/CaP regression grade is prognostic, even after adjusting for established prognostic factors like pathologic stage, supports the validity of these criteria and argues strongly for their importance in the pathologic assessment of neoadjuvant-ly treated rectal cancer. furthermore, the fact that the 2 partial response categories defined by the aJCC/CaP are clinically significant and predict intermediate outcomes is a new and important finding. the fact that regression grade correlated significantly with important factors such as pathologic stage and angiolymphatic invasion posed challenges for our survival analyses. our comprehensive effort to control for these factors in multivariate analyses is another important strength of this study. a wide range of clinical data was analyzed for each patient included in this study, and supervised stepwise regression was used to select and control for all significant covariates for each survival and recurrence outcome. the results of these analyses show that aJCC/CaP grade influences oncologic outcome independent of other significant prognostic factors. We have also provided clinically useful risk ratios showing both the relative risk reduction associated with each aJCC/CaP grade compared with nonresponders (aJCC/CaP grade 3) and the risk ratio associated with any single aJCC/CaP grade increase.
our finding that aJCC/CaP regression grade correlates strongly with rectal cancer prognosis has important clinical implications. information from this study can be used in discussion with patients to improve the determination of rectal cancer prognosis. specifically, the findings of this study validate that aJCC/CaP regression grade is a clinical parameter, similar to pathologic stage, where each increment reliably predicts recurrence and survival. Knowledge about the implications of aJCC/CaP regression grade may be useful for determining prognosis or guiding treatment in unclear cases or in patients in whom pathologic staging is unreliable, such as patients with inadequate lymphadenectomy. Perhaps the most important implication of our study is to highlight the importance of reporting tumor regression grade and to encourage the widespread implementation of the aJCC/CaP regression grading criteria in hospital systems across the country.
although this is the first study to investigate the clinical relevance of the aJCC/CaP regression grading system per se, many authors have evaluated the prognostic significance of other rectal cancer regression grading systems. the definition of complete pathologic response is relatively uniform across all regression grading systems, and martin and colleagues 10 have conducted an excellent meta-analysis that demonstrated that complete pathologic response was associated with significantly improved survival and recurrence rates in a sample of 16 studies (3363 patients). the significantly improved outcome experienced by complete responders (aJCC/CaP grade 0) in this study is consistent with previous findings published by our group and many others. 7, [12] [13] [14] [15] incomplete response to neoadjuvant therapy is defined differently in each regression grading system. many authors have studied the 5-point regression grading system proposed by mandard and modified for rectal cancer by Dworak et al. 16 in addition to complete response and nonresponse grades, these systems define 3 partial response categories based on the percentage of tumor remaining after CRt. in studies by Rodel et al, 17 topova et al, 18 and others, [19] [20] [21] [22] the Dworak regression grading system was associated with differential oncologic outcomes in univariate analyses but was infrequently significant in multivariate analyses. more recently, studies by lim et al 23 and lin et al 24 have demonstrated that partial response grades defined by similar 5-point regression grading scales had prognostic importance in both univariate and multivariate analyses. in most studies, 5-point regression grading scales required simplification into 3 groups of grades to produce significant results, prompting several authors to evaluate novel 3-grade systems. these 3-grade scales have performed well as predictors of outcome in several studies, but the most significant contrast was typically that between complete responders versus all others. 11, 25, 26 in contrast to many of the previous reports evaluating 3-point and 5-point grading systems, we found that par-tial response grades established by the aJCC/CaP are predictive of distinct oncologic outcomes even after adjusting for other well-established prognostic factors. the lack of consensus about which grading system to use and what comparisons within each system are clinically important poses a significant challenge to the interpretation of the literature. 6 a recent publication by abdul-Jalil and colleagues 27 highlights these problems by comparing the prognostic performance of 5 different regression grading systems. the authors found that each grading system performed differently in the same patient population, and, although some regression grading systems performed well in univariate analyses, the prognostic value of all regression grades, with the exception of complete pathologic response, were insignificant in multivariate analyses that adjusted for established prognostic factors like pathologic stage. Consensus on regression grading is needed, and the aJCC/CaP guidelines offer a rational solution. they are practical guidelines supported by 2 major national panels on cancer staging, and the findings of our study support their prognostic value when applied clinically. like many previous authors, we found that known prognostic factors such as pathologic stage, angiolymphatic invasion, histologic margin status, and tumor perforation were still important and strongly influenced survival in our population. however, in contrast to most studies investigating other regression grading systems, we found that even after adjusting for established prognostic factors, aJCC/CaP regression grade was an independent predictor of oncologic outcome. for those reasons, we believe our findings demonstrate that the aJCC/CaP regression grading system is superior to previous regression grading scales. We recognize the potential limitations of this study. one limitation was imposed by the effects of event rate on our recurrence outcomes. event rate is a critical factor that determines resolution and significance of survival data. in the case of local recurrence, our population had a low overall recurrence rate (15.6%) and a very low local recurrence rate (2.4%) with no local recurrences in the aJCC/CaP grade 0 cohort. this low event rate severely limited the ability of individual variables to reach statistical significance in cumulative recurrence analyses and limited the power of this study to detect main effects and covariates influencing recurrence outcomes. similarly, our analysis of cancer-specific survival was made less sensitive than our analysis of overall and disease-free survival because of the censoring of patients with an unknown cause of death. additionally, this study was retrospective in nature and was more subject to bias from loss to follow-up, missed deaths, and missed recurrences than a prospectively designed study. We addressed this limitation by frequent chart audits, careful patient selection, and exclusion of patients missing important data. We addressed issues of loss to follow-up by incorporating a large population, which allowed us to achieve a 4.8-year median followup and sufficient power to detect survival differences.
CONCLUSIONS
this study defines the prognostic significance of aJCC/ CaP regression grading for patients with locally advanced rectal cancer treated with neoadjuvant therapy. each aJCC/CaP regression grade is associated with distinct probabilities of cancer recurrence and survival, even after adjusting for other significant prognostic factors. these findings highlight the importance of reporting tumor regression according to the aJCC/CaP criteria so that this important prognostic information is widely available to clinicians who treat rectal cancer.
